AGM
LGND icon

Alpine Global Management’s Ligand Pharmaceuticals LGND Stock Holding History

Alpine Global Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,500
Closed -$284K – 337
2025
Q4 		$284K Buy
+1,500
New +$288K 0.06% 127
2015
Q3 		– Sell
-1,706
Closed -$107K – 488
2015
Q2 		$107K Buy
+1,706
New +$93.1K 0.02% 558

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Alpine Global Management's LGND Position: Q1 2026 in Review

Alpine Global Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2026, closing a stake of 1,500 shares — an estimated $284K sold.

Alpine Global Management first reported a position in LGND in Q2 2015 and held it in 2 quarters. The position peaked at $284K in Q4 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Alpine Global Management reported no remaining Ligand Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Alpine Global Management sold 1,500 Ligand Pharmaceuticals shares in Q1 2026, an estimated $284K.
  • Alpine Global Management first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Alpine Global Management's Ligand Pharmaceuticals position peaked at $284K in Q4 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Alpine Global Management's 13F filing for Q1 2026, filed 15 May 2026.